Glaxo fires some China staff for malpractice amid stepped-up surveillance

With GlaxoSmithKline's ($GSK) China operations under investigation amid bribery allegations, the company is keeping its employees there under a more watchful eye. As Reuters reports, that extra surveillance helped turn up failures to comply with expense rules, leading to the firing of some staffers for malpractice. "Where we have found potential issues, we are thoroughly reviewing them and have withheld incentive payments where appropriate," a Glaxo spokesman told the news service. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.